Home » FDA Pushes Back Comment Period on Hep C Drug Development Guidance
FDA Pushes Back Comment Period on Hep C Drug Development Guidance
The FDA has extended the comment period for its draft guidance for developing direct-acting antiviral hepatitis C drugs to July 19.
The agency attributes the extension to maintenance on the Federal eRulemaking portal from July 1 through July 5.
The draft guidance, which recommended that companies factor in interferon treatment when designing clinical trials, previously was released for comment in May.
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May